Antibiotic susceptibility in prostate-derived Propionibacterium acnes isolates

APMIS

Volumn 120, Issue 10, 2012, Pages 778-785

  Olsson, Jan ^a   Davidsson, Sabina ^b   Unemo, Magnus ^b   Mölling, Paula ^b   Andersson, Swen Olov ^b   Andrén, Ove ^b   Söderquist, Bo ^b   Sellin, Mats ^a   Elgh, Fredrik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic; Cancer; Propionibacterium; Prostate; Prostatitis

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; IMIPENEM; LINEZOLID; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULFADOXINE PLUS TRIMETHOPRIM; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; ERADICATION THERAPY; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROSTATE; PROSTATE CANCER;

ANTI-BACTERIAL AGENTS; BIOPSY, NEEDLE; CULTURE MEDIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PROPIONIBACTERIUM ACNES; PROSTATE; PROSTATIC NEOPLASMS; SKIN; SWEDEN;

EID: 84866150414     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02905.x     Document Type: Article

References (50)

1. Bojar RA, Holland KT. Acne and Propionibacterium acnes. Clin Dermatol 2004;22:375-9.
2. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? Br J Dermatol 2008;158:442-55.
3. Tammelin A, Hambraeus A, Stahle E. Mediastinitis after cardiac surgery: improvement of bacteriological diagnosis by use of multiple tissue samples and strain typing. J Clin Microbiol 2002;40:2936-41.
4. Holmberg A, Lood R, Morgelin M, Soderquist B, Holst E, Collin M, et al. Biofilm formation by Propionibacterium acnes is a characteristic of invasive isolates. Clin Microbiol Infect 2009;15:787-95.
5. Millett PJ, Yen YM, Price CS, Horan MP, van der Meijden OA, Elser F. Propionibacterium acnes infection as an occult cause of postoperative shoulder pain: a case series. Clin Orthop Relat Res 2011;469:2824-30.
6. Clayton JJ, Baig W, Reynolds GW, Sandoe JA. Endocarditis caused by Propionibacterium species: a report of three cases and a review of clinical features and diagnostic difficulties. J Med Microbiol 2006;55(Pt 8):981-7.
7. Furukawa A, Uchida K, Ishige Y, Ishige I, Kobayashi I, Takemura T, et al. Characterization of Propionibacterium acnes isolates from sarcoid and non-sarcoid tissues with special reference to cell invasiveness, serotype, and trigger factor gene polymorphism. Microb Pathog 2009;46:80-7.
8. Colina M, Lo Monaco A, Khodeir M, Trotta F. Propionibacterium acnes and SAPHO syndrome: a case report and literature review. Clin Exp Rheumatol 2007;25:457-60.
9. Jakab E, Zbinden R, Gubler J, Ruef C, von Graevenitz A, Krause M. Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections. Yale J Biol Med 1996;69:477-82.
10. Nisbet M, Briggs S, Ellis-Pegler R, Thomas M, Holland D. Propionibacterium acnes: an under-appreciated cause of post-neurosurgical infection. J Antimicrob Chemother 2007;60:1097-103.
11. Chia JK, Nakata MN. Intervertebral diskitis caused by Propionibacterium acnes: a report of four cases. Clin Infect Dis 1996;23:643-4.
12. Lalani T, Person AK, Hedayati SS, Moore L, Murdoch DR, Hoen B, et al. Propionibacterium endocarditis: a case series from the International Collaboration on Endocarditis Merged Database and Prospective Cohort Study. Scand J Infect Dis 2007;39:840-8.
13. Hinestrosa F, Djurkovic S, Bourbeau PP, Foltzer MA. Propionibacterium acnes as a cause of prosthetic valve aortic root abscess. J Clin Microbiol 2007;45:259-61.
14. Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother 2005;6:409-18.
15. Hayashi N, Kawashima M. Efficacy of oral antibiotics on acne vulgaris and their effects on quality of life: a multicenter randomized controlled trial using minocycline, roxithromycin and faropenem. J Dermatol 2011;38:111-9.
16. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998;196:130-4.
17. Kinney MA, Yentzer BA, Fleischer AB Jr, Feldman SR. Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance? J Drugs Dermatol 2010;9:519-24.
18. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol 2010;9:655-64.
19. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005;173:1969-74.
20. Alexeyev O, Bergh J, Marklund I, Thellenberg-Karlsson C, Wiklund F, Gronberg H, et al. Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control 2006;17:1127-33.
21. Fassi Fehri L, Mak TN, Laube B, Brinkmann V, Ogilvie LA, Mollenkopf H, et al. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int J Med Microbiol 2011;301:69-78.
22. Unemo M, Friberg O, Enquist E, Kallman J, Soderquist B. Genetic homogeneity/heterogeneity of Propionibacterium acnes isolated from patients during cardiothoracic reoperation. Anaerobe 2007;13:121-6.
23. Soderquist B, Holmberg A, Unemo M. Propionibacterium acnes as an etiological agent of arthroplastic and osteosynthetic infections - two cases with specific clinical presentation including formation of draining fistulae. Anaerobe 2010;16:304-6.
24. McDowell A, Valanne S, Ramage G, Tunney MM, Glenn JV, McLorinan GC, et al. Propionibacterium acnes types I and II represent phylogenetically distinct groups. J Clin Microbiol 2005;43:326-34.
25. Steward CD, Raney PM, Morrell AK, Williams PP, McDougal LK, Jevitt L, et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Cli Microbiol 2005;43:1716-21.
26. European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 1.3, 2011. http://www.eucast.org/clinical_breakpoints. (accessed 7 May 2011).
27. Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005;11:204-13.
28. Magri V, Trinchieri A, Ceriani I, Marras E, Perletti G. Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome. Arch Ital Urol Androl 2007;79:93-8.
29. Giannopoulos A, Koratzanis G, Giamarellos-Bourboulis EJ, Panou C, Adamakis I, Giamarellou H. Pharmacokinetics of clarithromycin in the prostate: implications for the treatment of chronic abacterial prostatitis. J Urol 2001;165:97-9.
30. Krieger JN, Ross SO, Limaye AP, Riley DE. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005;66:721-5.
31. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62:537-41.
32. Wagenlehner FM, Naber KG. Antimicrobial treatment of prostatitis. Expert Rev Anti Infect Ther 2003;1:275-82.
33. Nickel JC, Xiang J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J Urol 2008;179:1391-5.
34. Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011;305:78-86.
35. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001;40:576-88.
36. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy 2003;49:269-79.
37. Swedish Reference Group for Antibiotics. Current views on antibiotics, Tigecyclin, 2010. http://www.srga.org/ABSPEC/2010/Tigecyklin%20101216.pdf (accessed 7 May 2011).
38. Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol New Drugs 1972;12:259-62.
39. Hoogkamp-Korstanje JA, de Leur EJ, Franssens D. The influence of prophylactic piperacillin on the postoperative course of transurethral prostatectomy. J Antimicrob Chemother 1985;16:773-9.
40. Geerlings SE, van Donselaar-van der Pant KA, Keur I. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 2010;65:2048-9.
41. Slatter JG, Sams JP, Easter JA, Fate GD, Chiba K, Johnson MG, et al. Assessment of radioactive residues arising from radiolabel instability in a multiple dose tissue distribution study in rats. Biol Pharm Bull 2003;26:573-8.
42. Pronk MJ, Pelger RC, Baranski AG, van Dam A, Arend SM. Cure of chronic prostatitis presumably due to Enterococcus spp and gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006;25:270-1.
43. Lee Y, Huang W, Huang J, Wang J, Yu C, Jiaan B. Efficacy of chemotherapy for prostatic tuberculosis-a clinical and histologic follow-up study. Urology 2001;57:872-7.
44. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents 2008;31(Suppl 1):S112-6.
45. Magri V, Marras E, Skerk V, Markotic A, Restelli A, Garlaschi MC, et al. Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination. Andrologia 2010;42:366-75.
46. Friberg O, Svedjeholm R, Soderquist B, Granfeldt H, Vikerfors T, Kallman J. Local gentamicin reduces sternal wound infections after cardiac surgery: a randomized controlled trial. Ann Thorac Surg 2005;79:153-61; discussion 61-2.
47. Friberg O, Svedjeholm R, Kallman J, Soderquist B. Incidence, microbiological findings, and clinical presentation of sternal wound infections after cardiac surgery with and without local gentamicin prophylaxis. Eur J Clin Microbiol Infect Dis 2007;26:91-7.
48. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006;26:1099-110.
49. Lomholt HB, Kilian M. Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS ONE 2010;5:e12277.
50. Oprica C, Emtestam L, Lapins J, Borglund E, Nyberg F, Stenlund K, et al. Antibiotic-resistant Propionibacterium acnes on the skin of patients with moderate to severe acne in Stockholm. Anaerobe 2004;10:155-64.